9-(α-L-lyxofuranosyl)adenine | 258355-44-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(α-L-lyxofuranosyl)adenine
• 英文别名: 1-(6-amino-purin-9-yl)-β-L-1-deoxy-lyxofuranose；β-Adenosin；(2S,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 258355-44-1
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.244
• InChiKey: OIRDTQYFTABQOQ-WDHZHIADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9-(α-L-lyxofuranosyl)adenine 在 E_. coli purine nucleoside phosphorylase 作用下， 生成 腺嘌呤 、
  参考文献：
  名称：

  Gene Therapy of Cancer: Activation of Nucleoside Prodrugs withE. coliPurine Nucleoside Phosphorylase

  摘要：

  During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery off. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.

  DOI：

  10.1080/15257779908041562

文献信息

• [EN] METHODS OF TREATING CANCER USING CHECKPOINT INHIBITORS IN COMBINATION WITH PURINE CLEAVING ENZYMES<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER METTANT EN ŒUVRE DES INHIBITEURS DE POINT DE CONTRÔLE EN COMBINAISON AVEC DES ENZYMES DE CLIVAGE DES BASES PURIQUES
  申请人：UNIV EMORY

  公开号：WO2021183640A1

  公开（公告）日：2021-09-16

  This disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme or a vector encoding expression thereof, and a prodrug cleaved by said purine cleaving enzyme. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme, or a vector encoding expression thereof, in the absence of a prodrug cleaved by said purine cleaving enzyme.